Evidence map›Paper›PMID 26862179›Full record

ReviewThe Biochemical journal2016

New photosensitizers for photodynamic therapy.

Heidi Abrahamse, Michael R Hamblin

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in The Biochemical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03380403 (A Clinical Trial Testing the Efficacy of PDT in Preventing Amputation in Diabetic Patients), which is not on this map. Cited by 637 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
637citing papers in PubMed, 1 pooled it
78.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03380403 nacompletednot on this map

A Clinical Trial Testing the Efficacy of PDT in Preventing Amputation in Diabetic Patients

TypeinterventionalSponsorFaculdade de Medicina do ABCRan2010 to 2012Enrolled34ConditionsDiabetic Foot Infection, Osteomyelitis, Photo Antimicrobial ChemotherapyArmsPDT, Ciprofloxacin
3 · Its place in the literature

Who cites it

637 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,938 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Linker dependence ofOrganic & biomolecular chemistry · 2026
    Article
  17. Article
  18. Identification and characterization of phyllochlorin sodium as a novel chlorin-derived photosensitiser.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  19. Antimicrobial photodynamic therapy using tetra-cationic porphyrins with peripheral platinum(II) and palladium(II) complexes against multidrug-resistant bacteria isolated from canine otitis.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  20. Article

577 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Heidi AbrahamseLaser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, U.S.A. Department of Dermatology, Harvard Medical School, Boston, MA 02115, U.S.A. Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, U.S.A. Hamblin@helix.mgh.harvard.edu.
University of Johannesburg · ZA

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
NIAID NIH HHS R01 AI050875NIAID NIH HHS R01AI050875
6 · The paper itself

Abstract

Photodynamic therapy (PDT) was discovered more than 100 years ago, and has since become a well-studied therapy for cancer and various non-malignant diseases including infections. PDT uses photosensitizers (PSs, non-toxic dyes) that are activated by absorption of visible light to initially form the excited singlet state, followed by transition to the long-lived excited triplet state. This triplet state can undergo photochemical reactions in the presence of oxygen to form reactive oxygen species (including singlet oxygen) that can destroy cancer cells, pathogenic microbes and unwanted tissue. The dual-specificity of PDT relies on accumulation of the PS in diseased tissue and also on localized light delivery. Tetrapyrrole structures such as porphyrins, chlorins, bacteriochlorins and phthalocyanines with appropriate functionalization have been widely investigated in PDT, and several compounds have received clinical approval. Other molecular structures including the synthetic dyes classes as phenothiazinium, squaraine and BODIPY (boron-dipyrromethene), transition metal complexes, and natural products such as hypericin, riboflavin and curcumin have been investigated. Targeted PDT uses PSs conjugated to antibodies, peptides, proteins and other ligands with specific cellular receptors. Nanotechnology has made a significant contribution to PDT, giving rise to approaches such as nanoparticle delivery, fullerene-based PSs, titania photocatalysis, and the use of upconverting nanoparticles to increase light penetration into tissue. Future directions include photochemical internalization, genetically encoded protein PSs, theranostics, two-photon absorption PDT, and sonodynamic therapy using ultrasound.

Indexed as

PhotochemotherapyHumansNeoplasmsPhotosensitizing AgentsPhotosensitizing Agentsnaturally occurring photosensitizersphotochemical mechanismsphotodynamic therapyphotosensitizerssynthetic dyestetrapyrroles

Identifiers

PMID26862179
PMCPMC4811612
OpenAlexW2278726896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.